Mi-Vax (ONM-500)
/ OncoNano Medicine, UT Southwestern Medical Center
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 25, 2024
A phase 1 dose-escalation and expansion study of an intratumorally administered dual STING agonist (ONM-501) alone and in combination with cemiplimab in patients with advanced solid tumors and lymphomas.
(ASCO 2024)
- P1 | " ONM5001 (NCT06022029) is a first-in-human, open-label, multi-center clinical trial. Secondary endpoints include characterization of pharmacokinetics and pharmacodynamics, as well as initial efficacy based on RECIST evaluation criteria. Enrollment began in November 2023."
Clinical • Combination therapy • Metastases • P1 data • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor • STING
1 to 1
Of
1
Go to page
1